IMPORTANT INFORMATION
THIS INDUSTRY SESSION IS TAKING PLACE IN PHILADELPHIA, PENNSYLVANIA.
PLEASE NOTE: Only registered attendees of the ACR CONVERGENCE 2022 can attend this session in person.
OVERVIEW
If left uncontrolled, spondyloarthritis can cause progressive structural joint damage and irreversible disability. Early identification and treatment initiation is crucial for successful outcomes. In this symposium expert faculty will discuss the rationale for long-term disease control and how to improve standards of care based on shared decision making and patient characteristics and preferences. Recommendations on how to select treatments will be discussed in light of the latest clinical evidence.
GOAL STATEMENT
The goal of this activity is for learners to be better able to set treatment goals, conduct patient assessment and monitoring, and implement treatment selection/switching to achieve better control of disease in clinical practice.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the[list][item]Importance of limiting disease progression in spondyloarthritis[ITEM]Treat to target for spondyloarthritis[/LIST]Have greater competence related to[LIST] [ITEM]Individualizing treatment goals[/LIST]
ACCREDITATION STATEMENT
[JALOGO][MEDSCAPE] In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.5 [italic]AMA PRA Category 1 Credits[/italic]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Philadelphia Marriott Downtown - Grand Ballroom E
1201 Market Street (Guest entrance at 1200 Filbert Street)
Philadelphia, Pennsylvania, 19107
United States
This is not an official program of the American College of Rheumatology. This session will be conducted during ACR Convergence 2022.
Supported by an independent educational grant from UCB Pharma, Inc.